Sectra will lead EU research-project to decrease mortality in breast cancer

The Swedish IT and medical-technology company Sectra, together with clinical and industrial partners from six European countries, has been awarded EUR 3.6 million from the European Union to combat breast cancer through a research project for high-resolution, low-dose X-ray imaging.

Sectra MicroDose
Sectra MicroDose
The project comprises development of novel imaging methods based on Sectra´s photon-counting detector technology, which provides the unmatched lowest radiation dose on the market. The objective is to improve early detection and diagnosis of breast cancer and clinical evaluation of the new methods.

In the European Union (EU), breast cancer of all cancers is the most common cause of death for women below seventy years of age and this is one of the largest grants of this type ever awarded by the EU in its efforts to combat breast cancer.

The project is designated “High-Resolution X-ray Imaging for Improved Detection and Diagnosis of Breast Cancer” (HighReX) and will be part of the Sixth EU Framework Program for Research and Technological Development (FP6). Experienced mammography physicians from several European breast-imaging centers are involved in the project to test and evaluate the imaging techniques developed in the project and compare them to existing methods.

Low-dose initiative
In mammography screening operations, low radiation dose is an important factor since healthy women are examined on a relatively frequent number of occasions on a recurring basis. The EU strongly supports the ALARA principle. ALARA is an acronym for As Low As Reasonably Achievable. This is a radiation safety principle for minimizing radiation doses and releases of radioactive materials by employing all reasonable methods. ALARA is not only a sound safety principle but is a regulatory requirement for all radiation safety programs.
Sectra’s photon-counting detector technology
Sectra’s photon-counting detector technology is commercially available through Sectra MicroDose Mammography, a digital mammography system that produce excellent images with the decidedly lowest radiation dose of all systems on the market. Within the HighReX project, Sectra will develop and evaluate novel methods for breast cancer detection and diagnosis, such as 3D/tomosynthesis, dual-energy and contrast mammography. Providing low-dose images with significantly increased contrast and spatial resolution, Sectra’s detector technology is a perfect start for developing these methods.


More on the subject:More on companies:
Read all latest stories

Related articles


Article • IT security

What keeps a hospital’s immune system healthy?

‘You can’t get 100 percent security, you can’t avoid all risks – but you can improve security tremendously just by considering some rules,’ explains Torbjörn Kronander, Board member, CEO…


Sponsored • Digital Pathology

Take the next step in Digital Pathology

Digitizing pathology is not just a transformation of technology, the major change and benefits lies in the change to a more efficient workflow – enabled by the new technology.


Sponsored • Testing Bones

Osteoporosis risk assessments with DXR

Women over the age of 50 are not only at higher risk of developing breast cancer but also osteoporosis. Would it not be practical to use the same method to detect both diseases early on? Definitely,…

Related products

AB-CT · Advanced Breast-CT - nu:view

Mammo CT

AB-CT · Advanced Breast-CT - nu:view

AB-CT – Advanced Breast-CT GmbH
Canon · Vitrea Advanced Visualization


Canon · Vitrea Advanced Visualization

Canon Medical Systems Europe B.V.
Drtech Europe GmbH · Aidia

Digital Mammography

Drtech Europe GmbH · Aidia

Fujifilm · Amulet Bellus II

Mammo Workstations

Fujifilm · Amulet Bellus II

Subscribe to Newsletter